Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Vedanta Biosciences has secured a $25 million investment from Pfizer under its Breakthrough Growth Initiative. This funding will support a Phase 2 study of VE202 for treating inflammatory bowel disease (IBD), expected to start in 2021. Preliminary data from a Phase 1 study indicates that VE202 is safe and promotes durable colonization. IBD affects 1.6 million Americans, highlighting the urgent need for new treatments. Pfizer's Dr. Michael Vincent will join Vedanta's Scientific Advisory Board. Importantly, Vedanta retains control of its programs while granting Pfizer a right of first negotiation on VE202.
- Pfizer's $25 million investment supports Phase 2 study of VE202.
- Phase 1 study data indicates VE202 is generally safe and well-tolerated.
- VE202 demonstrated durable and dose-dependent colonization.
- Vedanta retains control over its programs.
- None.
Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE) has made a
Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021. Topline Phase 1 study data showed VE202 was generally safe and well-tolerated at all doses and demonstrated durable and dose-dependent colonization.
“We thank Pfizer for its investment in Vedanta and support of our IBD program and look forward to advancing microbiome modulation as a potential new treatment modality for IBD patients,” said Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences.
“Inflammatory bowel disease has a daily, chronic impact on as many as 1.6 million Americans, and with cases on the rise in the U.S., patients urgently need new therapeutic options,” said Michael Vincent, M.D., Ph.D., Senior Vice President and Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer. “We believe Vedanta’s approach to modulating the microbiome may hold promise for people living with IBD, and we are excited for its potential as this important study moves forward.”
As part of the investment, Dr. Vincent will join Vedanta’s Scientific Advisory Board. Vedanta will retain control of all its programs and has granted Pfizer a right of first negotiation on VE202.
About VE202
VE202 is a first-in-class orally administered investigational live biotherapeutic product (LBP) consisting of a defined bacterial consortium. It is produced under GMP conditions from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing of fecal donor material of inconsistent composition. VE202 was designed to induce immune tolerance via the gut and thereby potentially treat inflammatory bowel disease. Results describing the biology and candidate selection of VE202 were previously published in Science and Nature (multiple).
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What was the recent investment made by Pfizer in Vedanta Biosciences?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Pfizer invested $25 million in Vedanta Biosciences as part of the Breakthrough Growth Initiative."
}
},
{
"@type": "Question",
"name": "What will Vedanta use the proceeds from Pfizer's investment for?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Vedanta will use the funds to support a Phase 2 study of VE202 in inflammatory bowel disease."
}
},
{
"@type": "Question",
"name": "What are the results of the Phase 1 study of VE202?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The Phase 1 study showed that VE202 was generally safe, well-tolerated, and demonstrated durable colonization."
}
},
{
"@type": "Question",
"name": "How many Americans are affected by inflammatory bowel disease?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Inflammatory bowel disease impacts approximately 1.6 million Americans."
}
}
]
}
FAQ
What was the recent investment made by Pfizer in Vedanta Biosciences?
What will Vedanta use the proceeds from Pfizer's investment for?
What are the results of the Phase 1 study of VE202?
How many Americans are affected by inflammatory bowel disease?
